Evidence map›Paper›PMID 29246923›Full record

Observational studyHaematologica2018

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).

Ronan Le Calloch, Karine Lacut, Christelle Le Gall-Ianotto, Emmanuel Nowak, Morgane Abiven, Adrian Tempescul, Florence Dalbies, Jean-Richard Eveillard, Valérie Ugo, Stéphane Giraudier and 4 more

3 registry-linked trialsOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02893410 completednot on this map

Etude de l'Observance thérapeutique et Des Effets Secondaires Des Traitements Chez Les Patients traités Pour Polyglobulie de Vaquez et thrombocytémie Essentielle

TypeobservationalSponsorUniversity Hospital, BrestRan2014 to 2015Enrolled286ConditionsPolycythemia Vera, Essential Thrombocythemia
NCT02897297 recruitingnot on this map

Observatoire Brestois Des Néoplasies Myéloprolifératives

TypeobservationalSponsorUniversity Hospital, BrestRan2015 to 2025Enrolled1,000ConditionsPolycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis
NCT03599700 unknown statusnot on this mapstarted 2019, after this paper: background citation

Risk Factors and Predictors of Thrombosis in Patients With Philadelphia Negative Myeloprolferative Neoplasms

Typeobservational_patient_registrySponsorAssiut UniversityRan2019 to 2022Enrolled165ConditionsThrombosisArmsmyeloproliferative neoplasms
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Ronan Le CallochService de Médecine Interne-Maladies du Sang-Maladies Infectieuses (MIIS), CHIC de Quimper, France.
Karine LacutCIC 1412, INSERM, Brest, France.
Christelle Le Gall-IanottoLaboratoire Interactions Epitheliums-Neurones, EA 4685, Université de Bretagne Occidentale, France.
Emmanuel NowakCIC 1412, INSERM, Brest, France.
Morgane AbivenCIC 1412, INSERM, Brest, France.
Adrian TempesculFédération Inter Hospitalière d'Immuno-Hématologie de Bretagne Occidentale (FIHBO), France.
Florence DalbiesFédération Inter Hospitalière d'Immuno-Hématologie de Bretagne Occidentale (FIHBO), France.
Jean-Richard EveillardFédération Inter Hospitalière d'Immuno-Hématologie de Bretagne Occidentale (FIHBO), France.
Valérie UgoLaboratoire d'Hématologie, CHU d'Angers, France.
Stéphane GiraudierLaboratoire d'Hématologie, Hôpital St-Louis, AP-HP, Paris, France.
Gaëlle GuillermFédération Inter Hospitalière d'Immuno-Hématologie de Bretagne Occidentale (FIHBO), France.
Eric LippertLaboratoire d'Hématologie, CHRU de Brest and Equipe ECLA, INSERM U1078, Université de Bretagne Occidentale, Brest, France.
Christian BerthouFédération Inter Hospitalière d'Immuno-Hématologie de Bretagne Occidentale (FIHBO), France.
Jean-Christophe IanottoFédération Inter Hospitalière d'Immuno-Hématologie de Bretagne Occidentale (FIHBO), France jean-christophe.ianotto@chu-brest.fr.
Centre Hospitalier Régional Universitaire de Brest · FRUniversité de Bretagne Occidentale · FRCentre d'Immunologie et des Maladies Infectieuses · FRCentre Hospitalier Universitaire d'Angers · FRClinical Investigation Center Plurithematic Tours · FRHôpital Saint-Louis · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive drugs for polycythemia vera or essential thrombocythemia were recruited at our institution (

Indexed as

Drug MonitoringAdultAgedAged, 80 and overAge FactorsAntineoplastic AgentsFemaleFibrinolytic AgentsHumansMaleMiddle AgedPolycythemia VeraRisk FactorsSurveys and QuestionnairesThrombocythemia, EssentialAntineoplastic AgentsFibrinolytic Agents

Identifiers

PMID29246923
PMCPMC5865440
OpenAlexW2775099408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.